Peer-reviewed veterinary case report
Identification of lipid metabolism-associated biomarkers in lupus nephritis by SVM model and therapeutic potential of Alisol B 23-acetate.
- Journal:
- Gene
- Year:
- 2025
- Authors:
- Li, Rong et al.
- Affiliation:
- School of Basic Medical Science · China
Abstract
Systemic lupus erythematosus (SLE), a multifaceted autoimmune disorder, has lupus nephritis (LN) as one of its grave complications and is strongly associated with dyslipidemia. This investigation sought to delineate renal-specific lipid metabolism-related genes (LMRGs) signatures in lupus nephritis (LN) through integrated bioinformatics analysis and explore the therapeutic effect of Alisol B 23-acetate (ABA). Analysis of LN datasets revealed multiple dysregulated pathways and identified 11 key LMRGs, including CD36, associated with LN. In vitro, ABA suppressed CD36 activity, thereby reducing inflammation and lipid accumulation. In vivo, ABA improved lipid metabolism, attenuated immune cell infiltration, and ameliorated renal pathology. Renal lipid metabolic reprogramming exacerbates LN pathology, and ABA shows potential in treating LN by regulating key LMRGs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/40505998/